Interventional Oncology Approach to Hepatic Metastases

Abstract

Metastatic liver disease is one of the major causes of cancer-related morbidity and mortality. Locoregional therapies offered by interventional oncologists alleviate cancer-related morbidity and in some cases improve survival. Locoregional therapies are often palliative in nature but occasionally can be used with curative intent. This review will discuss important factors to consider prior to palliative and curative intent treatment of metastatic liver disease with locoregional therapy. These factors include those specific to the tumor, liver function, liver reserve, differences between treatment modalities, and patient-specific considerations.

Keywords

hepatic metastases - locoregional therapy - transarterial therapy - ablation - liver reserve

Publikationsverlauf

Artikel online veröffentlicht:
11. Dezember 2020

• References

• 1 Benson AB, Al-Hawary MM, Arain MA. et al. NCCN Guidelines Version 4.2020 Colon Cancer Continue NCCN Guidelines Panel Disclosures. 2020
• 2 Cummings MC, Simpson PT, Reid LE. et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol 2014; 232 (01) 23-31
• 3 Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008; 9 (11) 1092-1101
• 4 Mouli SK, Gupta R, Sheth N, Gordon AC, Lewandowski RJ. Locoregional therapies for the treatment of hepatic metastases from breast and gynecologic cancers. Semin Intervent Radiol 2018; 35 (01) 29-34
• 5 Benson AB, Abbott DE, Abrams TA. et al. NCCN Guidelines Version 3. Hepatobiliary Cancers. 2019
• 6 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
• 7 Covey AM, Brown KT, Jarnagin WR. et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008; 247 (03) 451-455
• 8 Simoneau E, Alanazi R, Alshenaifi J. et al. Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases. J Surg Oncol 2016; 113 (04) 449-455
• 9 Wiseman JT, Guzman-Pruneda F, Xourafas D. et al. Impact of neoadjuvant chemotherapy on the postoperative outcomes of patients undergoing liver resection for colorectal liver metastases: a population-based propensity-matched analysis. J Am Coll Surg 2019; 229 (01) 69-77.e2
• 10 Shindoh J, Tzeng CWD, Aloia TA. et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 2013; 20 (08) 2493-2500
• 11 Abulkhir A, Limongelli P, Healey AJ. et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247 (01) 49-57
• 12 Mahnken AH, Pereira PL, De Baère T. Interventional oncologic approaches to liver metastases. Radiology 2013; 266 (02) 407-430
• 13 Gabr A, Polineni P, Mouli SK, Riaz A, Lewandowski RJ, Salem R. Neoadjuvant radiation lobectomy as an alternative to portal vein embolization in hepatocellular carcinoma. Semin Nucl Med 2019; 49 (03) 197-203
• 14 de Baere T, Teriitehau C, Deschamps F. et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol 2010; 17 (08) 2081-2089
• 15 Elias D, De Baere T, Roche A, , Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999; 86 (06) 784-788
• 16 Collin Y, Paré A, Belblidia A. et al. Portal vein embolization does not affect the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: a prospective cohort study. Int J Surg 2019; 61: 42-47
• 17 Garlipp B, de Baere T, Damm R. et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology 2014; 59 (05) 1864-1873
• 18 Teo JY, Allen JC, Ng DC. et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford) 2016; 18 (01) 7-12
• 19 Gabr A, Abouchaleh N, Ali R. et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2018; 29 (11) 1502-1510.e1
• 20 Bösch F, Ilhan H, Pfahler V. et al. Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. Hepatobiliary Surg Nutr 2020; 9 (03) 312-321
• 21 Schadde E, Schnitzbauer AA, Tschuor C, Raptis DA, Bechstein WO, Clavien PA. Systematic review and meta-analysis of feasibility, safety, and efficacy of a novel procedure: associating liver partition and portal vein ligation for staged hepatectomy. Ann Surg Oncol 2015; 22 (09) 3109-3120
• 22 Wong SL, Mangu PB, Choti MA. et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28 (03) 493-508
• 23 Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13 (10) 1261-1268
• 24 Chen JX, Rose S, White SB. et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol 2017; 40 (01) 69-80
• 25 Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach”. Cancer 2003; 97 (12) 3027-3035
• 26 Malhotra A, Liu DM, Talenfeld AD. Radiation segmentectomy and radiation lobectomy: a practical review of techniques. Tech Vasc Interv Radiol 2019; 22 (02) 49-57
• 27 Aitken KL, Hawkins MA. Stereotactic body radiotherapy for liver metastases. Clin Oncol (R Coll Radiol) 2015; 27 (05) 307-315
• 28 Habermehl D, Herfarth KK, Bermejo JL. et al. Single-dose radiosurgical treatment for hepatic metastases--therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol 2013; 8 (01) 175
• 29 Lee J, Shin I-S, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol 2020; 145: 63-70
• 30 Lewandowski RJ, Gabr A, Abouchaleh N. et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 2018; 287 (03) 1050-1058
• 31 Meiers C, Taylor A, Geller B, Toskich B. Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. J Gastrointest Oncol 2018; 9 (02) 311-315
• 32 Tsitskari M, Filippiadis D, Kostantos C. et al. The role of interventional oncology in the treatment of colorectal cancer liver metastases. Ann Gastroenterol 2019; 32 (02) 147-155
• 33 Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005; 242 (02) 158-171
• 34 Shady W, Petre EN, Gonen M. et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes-a 10-year experience at a single center. Radiology 2016; 278 (02) 601-611
• 35 Sofocleous CT, Nascimento RG, Gonen M. et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007; 189 (04) 883-889
• 36 Nakazawa T, Kokubu S, Shibuya A. et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007; 188 (02) 480-488
• 37 Wahl DR, Stenmark MH, Tao Y. et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016; 34 (05) 452-459
• 38 Ohri N, Tomé WA, Méndez Romero A. et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 2018; (epub ahead of print)
• 39 Høyer M, Swaminath A, Bydder S. et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 2012; 82 (03) 1047-1057
• 40 Lu DSK, Raman SS, Limanond P. et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003; 14 (10) 1267-1274
• 41 Lu DSK, Yu NC, Raman SS. et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver 1. Radiological Society of North America. 2005 Available at: https://doi.org/10.1148/radiol.2343040153
• 42 Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics 2005; 25 (Suppl. 01) S69-S83
• 43 Shady W, Petre EN, Do KG. et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol 2018; 29 (02) 268-275.e1
• 44 Huo YR, Eslick GD. Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol 2015; 26 (08) 1139-1146.e2
• 45 Kalogeridi MA, Zygogianni A, Kyrgias G. et al. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J Hepatol 2015; 7 (01) 101-112
• 46 Foltz G. Image-guided percutaneous ablation of hepatic malignancies. Semin Intervent Radiol 2014; 31 (02) 180-186
• 47 Hamada A, Yamakado K, Nakatsuka A. et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol 2012; 30 (07) 567-574
• 48 Veltri A, Sacchetto P, Tosetti I, Pagano E, Fava C, Gandini G. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol 2008; 31 (05) 948-956
• 49 Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012; 265 (03) 958-968
• 50 Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK. Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res 2006; 26 1B (1B, 1b) 671-680
• 51 Ito H, Are C, Gonen M. et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008; 247 (06) 994-1002
• 52 Vogl TJ, Mack MG, Balzer JO. et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 2003; 229 (02) 457-464
• 53 Martin II RCG, Scoggins CR, Schreeder M. et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121 (20) 3649-3658
• 54 Gaba RC, Lokken RP, Hickey RM. et al; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol 2017; 28 (09) 1210-1223.e3
• 55 Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis. Digestion 2003; 68 (2-3): 94-101
• 56 Kitano M, Davidson GW, Shirley LA. et al. Transarterial chemoembolization for metastatic neuroendocrine tumors with massive hepatic tumor burden: Is the benefit worth the risk?. Ann Surg Oncol 2016; 23 (12) 4008-4015
• 57 Kamat PP, Gupta S, Ensor JE. et al. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol 2008; 31 (02) 299-307
• 58 Klimkowski S, Baker JC, Brown DB. Red flags, pitfalls, and cautions in Y90 radiotherapy. Tech Vasc Interv Radiol 2019; 22 (02) 63-69
• 59 Ho S, Lau WY, Leung TWT. et al. Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. Br J Radiol 1997; 70 (836) 823-828
• 60 Lau WY, Kennedy AS, Kim YH. et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 2012; 82 (01) 401-407
• 61 Hickey R, Lewandowski RJ, Prudhomme T. et al. 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med 2016; 57 (05) 665-671
• 62 Titano JJ, Kim E, Patel RS. Yttrium-90 complications: prevention and management. Tech Vasc Interv Radiol 2019; 22 (02) 87-92
• 63 Kim W, Clark TWI, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12 (08) 965-968
• 64 Atassi B, Bangash AK, Lewandowski RJ. et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 2008; 19 (05) 691-697
• 65 Geschwind JFH, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Kobeiter H. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002; 13 (11) 1163-1166
• 66 Khan W, Sullivan KL, McCann JW. et al. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol 2011; 197 (02) W343-W345
• 67 Padia SA. Y90 clinical data update: cholangiocarcinoma, neuroendocrine tumor, melanoma, and breast cancer metastatic disease. Tech Vasc Interv Radiol 2019; 22 (02) 81-86
• 68 Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray Jr CE, Gaba RC. Conventional ethiodized oil transarterial chemoembolization for treatment of hepatocellular carcinoma: contemporary single-center review of clinical outcomes. AJR Am J Roentgenol 2016; 206 (03) 645-654
• 69 Poggi G, Pozzi E, Riccardi A. et al. Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver. Anticancer Res 2010; 30 (12) 5159-5164
• 70 Salem R, Lewandowski RJ, Kulik L. et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140 (02) 497-507.e2
• 71 Tomozawa Y, Jahangiri Y, Pathak P. et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol 2018; 29 (06) 858-865
• 72 Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol 2019; 30 (12) 1915-1923
• 73 Su YK, Mackey RV, Riaz A. et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol 2017; 28 (11) 1520-1526
• 74 Boas FE, Bodei L, Sofocleous CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med 2017; 58 (Suppl. 02) 104S-111S
• 75 Lewandowski RJ, Donahue L, Chokechanachaisakul A. et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol 2016; 114 (01) 99-105
• 76 Vouche M, Lewandowski RJ, Atassi R. et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013; 59 (05) 1029-1036
• 77 Sandström P, Røsok BI, Sparrelid E. et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). Ann Surg 2018; 267 (05) 833-840
• 78 de Liguori Carino N, van Leeuwen BL, Ghaneh P, Wu A, Audisio RA, Poston GJ. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol 2008; 67 (03) 273-278
• 79 Livraghi T, Meloni F, Di Stasi M. et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?. Hepatology 2008; 47 (01) 82-89
• 80 Takaki H, Yamakado K, Nakatsuka A. et al. Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions: single-center experience. AJR Am J Roentgenol 2013; 200 (03) 658-664
• 81 Albert M, Kiefer MV, Sun W. et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117 (02) 343-352
• 82 Peterson JL, Vallow LA, Johnson DW. et al. Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: an evaluation of 112 patients. Brachytherapy 2013; 12 (06) 573-579
• 83 Gil-Alzugaray B, Chopitea A, Iñarrairaegui M. et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57 (03) 1078-1087